Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis

Fig. 2

Comparison of changes of each item between the 12-month period in Pre-MPZ and Post-MPZ. a Changes in BVAS, b increase in VDI, c reduction in peripheral eosinophil counts (/μL), and d accumulated concomitant CS dose (mg/year). BVAS, Birmingham vasculitis activity score; CS, corticosteroid; VDI, vasculitis damage index. P values were determined by Wilcoxon signed-rank test. *P < 0.05: Pre-MPZ vs. Post-MPZ

Back to article page